{Reference Type}: Journal Article
{Title}: Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study.
{Author}: Alammari Y;Albednah FA;Alharbi KA;Alrashoudi AM;Alsharif AY;Alkahtani AH;Alshehry HZ;Alajaji AA;Alsaedi AM;Al Harbi K;Qutob RA;Almansour M;
{Journal}: Cureus
{Volume}: 16
{Issue}: 4
{Year}: 2024 Apr
暂无{DOI}: 10.7759/cureus.57842
{Abstract}: <B>BACKGROUND: </B>Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition affecting multiple systems. Cardiovascular morbidity is a significant concern, with around 25% of SLE patients experiencing cardiac complications.<BR><B>OBJECTIVE: </B>This study aims to determine the prevalence of cardiovascular morbidity in SLE patients in King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia.<BR><B>METHODS: </B>This retrospective record-based research was conducted at KFMC from January 2015 to October 2023. A review of the medical files of all SLE patients was accomplished.<BR><B>RESULTS: </B>The vast majority of the patients (90.9%) were females. The mean age for the patients was 36.5 years. The most common comorbidities were lupus nephritis (34.6%), hypothyroidism (18.4%), and anti-phospholipid syndrome (9.2%). The most commonly used medications were hydroxychloroquine (81.8%), corticosteroids (prednisolone) (43.0%), and mycophenolate mofetil (27.9%). Around 45.2% (n= 176) of the patients with SLE developed cardiovascular complications. The most commonly reported cardiovascular diseases that developed after diagnosing patients with SLE were hypertension (22.4%), valvular heart diseases (13.2%), and dyslipidemia (9.2%). The study also found that anti-dsDNA antibodies can reduce the likelihood of developing hypertension by 40%. This research contributes to the medical literature on SLE and sets the stage for future research on personalized healthcare strategies for managing SLE and its complications.<BR><B>CONCLUSIONS: </B>This study highlights that a considerable proportion of SLE patients(~50%) develop cardiovascular complications, with hypertension, valvular heart diseases, and dyslipidemia being the most common. We also discovered that anti-double-stranded deoxyribonucleic acid antibodies (Anti-dsDNA) reduce the likelihood of developing hypertension.